Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Expiring patents (≤24 months)

Patent cliff watchlist — pharmaceutical patents approaching loss of exclusivity.

Patents
1,253

Quick answer

1,253 pharmaceutical patents in our index expire within the next 24 months. Use year facets below for annual patent-cliff planning linked to company and drug profiles.

  1. US 7291348

    Compositions and methods for biodegradable microspheres as carriers of bioactive substances

    The Board of Regents of the University of Texas System · Granted Tue Nov 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7291336

    Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Nov 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7291603

    Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations

    PTC THERAPEUTICS, INC. · Granted Tue Nov 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7291611

    Benzimidazolidinone derivatives as muscarinic agents

    ACADIA Pharmaceuticals Inc. · Granted Tue Nov 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7291614

    Processes for the preparation of linezolid intermediate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7294687

    Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7294475

    Gene and use thereof

    Takeda Chemical Industries Ltd. · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7294480

    High throughput screening assays using fatty acid synthetic enzymes

    Xenon Pharmaceuticals Inc. · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7294344

    Sustained-release preparation for AII antagonist, production and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7294496

    Cloned human lysophospholipase

    The Regents of the University of California · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7294699

    Modified vitamin K-dependent polypeptides

    Regents of the University of Minnesota · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7294735

    Purification of cinacalcet

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7297523

    Human elongase genes and uses thereof

    Xenon Pharmaceuticals Inc. · Granted Tue Nov 20 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7297488

    Identifying and testing antisense oligonucleotides that inhibit telomerase reverse transcriptase

    The Regents of the University of Colorado · Granted Tue Nov 20 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7300935

    Thienopyrimidine compounds and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7300660

    Abundant extracellular products and methods for their production and use

    The Regents of the University of California · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7300940

    Integrin α-v β-3 antagonists for use in imaging and therapy

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7300650

    Reovirus for the treatment of neoplasia

    ONCOLYTICS BIOTECH INC. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7300653

    Method of treating corneal transplant rejection

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7300654

    Method of treating corneal transplant rejection in high risk keratoplasty patients

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7300919

    Pulmonary delivery of active fragments of parathyroid hormone

    Nektar Therapeutics · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7300920

    Antiangiogenic peptide agents

    The Regents of the University of California · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7300915

    Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain

    The Regents of the University of California · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7300774

    Multimeric fusion proteins of the TNF superfamily ligands

    The Regents of the University of California · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7300928

    Benzimidazolidinone derivatives as muscarinic agents

    ACADIA Pharmaceuticals Inc. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7300949

    Thiazolopyrazoles and methods of their use

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7301024

    Crystalline forms of gatifloxacin and processes for preparation

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7301004

    Process for preparing glycopeptide phosphonate derivatives

    Theravance, Inc. · Granted Tue Nov 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7303747

    Use of VEGF inhibitors for treatment of eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7304071

    Protein kinase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7303746

    Methods of treating eye disorders with modified chimeric polypeptides

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7303887

    Mule: Mcl-1 ubiquitination ligase E3

    The Board of Regents of the University of Texas System · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7303748

    Method of treating eye injury with local administration of a VEGF inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7303751

    Anti-plasmodium compositions and methods of use

    The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7303754

    MVA expressing modified HIV envelope, gag, and pol genes

    The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7303881

    Antigen delivery compositions and methods of use

    PDS Biotechnology Corporation · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7304061

    Heterocyclic inhibitors of ERK2 and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7304069

    Hydrate of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5α]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto

    Neurocrine Biosciences, Inc. · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7304079

    Substituted indolealkanoic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7304127

    Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use

    UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7304080

    Substituted 1,2,4-oxadiazoles, compositions and methods of use

    PTC THERAPEUTICS, INC. · Granted Tue Dec 04 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7306799

    Use of VEGF inhibitors for treatment of eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7306804

    HIV-specific T-cell induction

    The Board of Regents of the University of Texas System · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7306808

    Orientia tsutsugamushi truncated recombinant outer membrane protein (r47) and (r57) vaccines diagnostics and therapeutics for scrub typhus

    United States of America as represented by the Secretary of the Air Force · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7306946

    Antifungal polypeptides

    The Regents of the University of California · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7306627

    Acellular matrix grafts of collagen and elastic fiber

    The Regents of the University of California · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7306632

    Leave-in color conditioner

    HairMarker LLC · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7306787

    Engineered particles and methods of use

    Nektar Therapeutics · Granted Tue Dec 11 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is a patent cliff?

A patent cliff is when key pharmaceutical patents expire, opening markets to generics or biosimilars. This hub lists USPTO patents with approaching expiration dates.

Are expiration dates estimates?

Expiration dates derive from USPTO PatentsView grant dates and term estimates. Confirm with Orange Book, patent counsel, and USPTO records before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.